SRZN
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Surrozen Inc (SRZN) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-03 | C+ (2.7) | C+ (2.8) | C+ (2.7) | C (2.4) | C- (2.0) | C+ (2.5) |
| 2026-08-02 | C+ (2.7) | C+ (2.8) | C+ (2.6) | C (2.4) | C- (1.9) | C+ (2.5) |
| 2026-07-29 | C+ (2.7) | C+ (2.5) | C (2.3) | C (2.3) | D+ (1.5) | C (2.3) |
| 2025-06-30 | C+ (2.7) | C+ (2.5) | C (2.4) | C (2.3) | D+ (1.5) | C (2.3) |
| 2025-03-31 | C+ (2.7) | C+ (2.5) | D- (1.0) | C (2.4) | D+ (1.5) | C- (2.0) |